Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106246 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL28666005 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL18986940 | 1.00 | NR1H2 (0.58) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL20554188 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL4525698 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL28375692 | 0.93 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL23906106 | 0.90 | NR1H2 (0.64) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL21561564 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27440647 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL17630406 | 0.89 | NR1H2 (0.63) | NR1H2CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| CN-110818704-B | Spiro bridged ring compounds, pharmaceutical compositions thereof and uses thereof | 广州市恒诺康医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-109790149-B | Phenoxytriazoles | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-108368112-B | Therapeutic compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3390402-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | NR1H2 666/4885CHRM2 1382/4885CHRM1 1530/4885 |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | NR1H2 869/4885CHRM2 4756/4885CHRM1 4827/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | NR1H2 1745/4885CHRM2 2009/4885CHRM1 1931/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | NR1H2 1745/4885CHRM2 2009/4885CHRM1 1931/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | NR1H2 270/4885CHRM2 1027/4885CHRM1 1164/4885 |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | NR1H2 869/4885CHRM2 4756/4885CHRM1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.